| At a glance | Inflammatory syndrome of shoulder and hip girdle stiffness in adults over 50; dramatic response to low-dose steroids. | Centralized pain syndrome with widespread tenderness, fatigue, and sleep and cognitive disturbance; normal labs and imaging. |
|---|
| Classic presentation | Subacute onset of bilateral shoulder and hip girdle aching and stiffness; Morning stiffness >45 minutes (often hours); Difficulty rising from a chair or lifting arms above the head; Constitutional symptoms in 30-50%: fatigue, low-grade fever, anorexia, weight loss; No true muscle weakness once pain is controlled; Restricted active… | Diffuse musculoskeletal pain >3 months in multiple body regions, often migratory; Profound fatigue, especially morning fatigue and after exertion; Nonrestorative sleep, frequent awakenings; Cognitive symptoms — word-finding difficulty, decreased concentration ('fibro fog'); Headache, paresthesias, dizziness; GI symptoms (IBS overlap),… |
|---|
| Workup / key labs | 2012 EULAR/ACR provisional criteria: age ≥50, bilateral shoulder pain, abnormal CRP or ESR, plus weighted morning stiffness, hip involvement, absence of other joint pain, and absence of RF/anti-CCP.; ESR — characteristically >40 mm/h (often >50-100); CRP elevated and may be more sensitive; CBC — normochromic normocytic anemia,… | 2016 revised fibromyalgia criteria (Wolfe et al.): widespread pain index (WPI) and symptom severity scale (SSS) — pain in 4 of 5 body regions for ≥3 months with WPI ≥7 and SSS ≥5 (or WPI 4-6 and SSS ≥9); the diagnosis is valid irrespective of other diagnoses, so coexisting RA, SLE, or OA does not exclude it.; Goal is to exclude… |
|---|
| Imaging | Shoulder ultrasound or MRI — subacromial-subdeltoid bursitis, biceps tenosynovitis, glenohumeral synovitis (supportive but not required); Temporal artery ultrasound or biopsy if GCA features develop; PET-CT in atypical cases — can show large-vessel uptake | Generally NOT indicated — incidental findings on MRI commonly mislead; Image only if focal red-flag findings emerge (true weakness, focal joint signs, neurologic deficits) |
|---|
| First-line treatment | Prednisone 12.5-25 mg/day — dramatic improvement within 48-72 hours is both therapeutic and diagnostic; Slow taper over 1-2 years guided by symptoms and inflammatory markers (EULAR/ACR 2015: taper to 10 mg/day within 4-8 weeks, then by 1 mg every 4 weeks until discontinuation while remission is maintained); Bone-protective therapy:… | Patient education — emphasize that pain is real, reflects altered central pain processing, and is not destructive or progressive; Aerobic exercise — graded, low-impact (walking, swimming, cycling); cornerstone of treatment; Sleep hygiene and treatment of sleep disorders (OSA, restless legs); Cognitive behavioral therapy and… |
|---|